Guangyuan Li

Zhengzhou Key Laboratory Of Lipid Metabolism And Precision Diagnosis & Treatment In Oncology
Zhengzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Correction: Overcoming chemoresistance in esophageal cancer with synergistic strategies.

Correction: Overcoming chemoresistance in esophageal cancer with synergistic strategies.

Journal: Frontiers in immunology

Published: June 24, 2026

Phosphorylation at Ser182 and Thr186 blocks GSDMD pyroptotic activity.

Phosphorylation at Ser182 and Thr186 blocks GSDMD pyroptotic activity.

Journal: Cellular signalling

Published: February 04, 2026

Overcoming chemoresistance in esophageal cancer with synergistic strategies.

Overcoming chemoresistance in esophageal cancer with synergistic strategies.

Journal: Frontiers in immunology

Published: January 09, 2026

Caspase-3 activation is a brake in GSDMD-mediated pyroptosis.

Caspase-3 activation is a brake in GSDMD-mediated pyroptosis.

Journal: Cellular signalling

Published: January 08, 2026

AMPK-PP1/PP2 axis regulates GSDMD-mediated pyroptosis via phosphorylation.

AMPK-PP1/PP2 axis regulates GSDMD-mediated pyroptosis via phosphorylation.

Journal: Frontiers in oncology

Published: November 02, 2025

Chemically induced dimerization of GSDMD C-terminal domain blocks GSDMD N-terminal domain-mediated pyroptosis.

Chemically induced dimerization of GSDMD C-terminal domain blocks GSDMD N-terminal domain-mediated pyroptosis.

Journal: Cell death discovery

Published: April 13, 2025

MT1H inhibits the growth of gastric cancer by regulating SLC6A19/TTC39B/ADM2 and activating p53-dependent autophagy.

MT1H inhibits the growth of gastric cancer by regulating SLC6A19/TTC39B/ADM2 and activating p53-dependent autophagy.

Journal: Scientific reports

Published: December 14, 2024

Pinpointing the integration of artificial intelligence in liver cancer immune microenvironment.

Pinpointing the integration of artificial intelligence in liver cancer immune microenvironment.

Journal: Frontiers in immunology

Published: October 31, 2024

Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study.

Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study.

Journal: Cancer medicine

Published: July 31, 2023

Showing 1-9 of 9

Last Updated: 09/26/2026